Form 8.5 (EPT/RI)-Advanced Medical Solutions Group plc

Investec Bank, acting as adviser and joint broker to Advanced Medical Solutions Group, disclosed client-serving trades on 21 September 2026 under UK Takeover Code Rule 8.5. It purchased 1,240,174 ordinary shares at 281.5p-282.25p and sold 1,172,056 shares at 282p-282.25p, for a net purchase of 68,118 shares. The filing reported no derivative activity or related indemnity, option, or other dealing arrangements.

Analysis

This disclosure is primarily evidence of routine client-serving inventory turnover by Investec rather than proprietary directional conviction. The near-offsetting share purchases and sales leave a de minimis net position relative to the gross activity, so neither INVP nor Advanced Medical Solutions Group (AMS.L) should be read through as having a fundamental catalyst. The practical implication is modestly improved displayed liquidity around the disclosed price area, not a change in takeover probability or consideration value.

For AMS.L, the relevant signal is whether repeated broker flow can absorb event-driven supply without a widening discount to any implied offer value. A persistent price decline despite intermediated liquidity would be more informative than this filing: it can indicate arbitrage capital reducing exposure, perceived execution risk, or a weakening expectation of a superior bid. Over the next 1-3 months, the only actionable catalysts are formal offer documentation, a revised timetable, financing/regulatory developments, or a material spread move; absent those, this is noise. INVP's earnings sensitivity to this isolated facilitation activity is immaterial, and no multiple re-rating case follows from the disclosure.

Key Decisions for Investors

• No standalone trade in INVP: do not treat the disclosed flow as a revenue, balance-sheet, or directional signal. Reassess only if advisory fee economics or a broader UK mid-market M&A pipeline becomes visible in results/guidance.
• For existing AMS.L merger-arbitrage exposure, monitor the spread to any announced or implied consideration daily for 1-3 months; reduce exposure if the spread widens materially without a market-wide risk-off explanation, as that would be a more credible execution-risk signal than broker dealing.
• Set an alert for a formal offer update, Panel timetable revision, or competing-bid indication in AMS.L. A documented change in transaction terms—not intermediary turnover—would justify recalibrating position size and downside to the standalone trading value.